Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balinatunfib - Sanofi

Next Previous
Drug Profile

Balinatunfib - Sanofi

Alternative Names: SAR-441566

Latest Information Update: 16 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Amines; Anti-inflammatories; Antirheumatics; Azabicyclo compounds; Benzimidazoles; Cyclobutanes; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Ketones; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Inflammation

Most Recent Events

  • 16 Sep 2025 Chemical structure information added.
  • 01 Aug 2025 Sanofi completes a phase I trial in Healthy volunteers in Belgium (PO) (CTIS2024-519860-41-00)
  • 02 Jul 2025 Sanofi completes a phase II SPECIFI-RA trial in Rheumatoid arthritis in the US, Argentina, Brazil, Canada, Chile, China, Czechia, Georgia, Germany, Greece, India, Japan, Mauritius, Mexico, Poland, Puerto Rico, Slovakia, South Africa and Spain(PO) (NCT06073093)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top